Alfa-foetoprotein response in patients with liver cancer treated with sorafenib - use in predicting outcome and response.
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2014
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics
- 22 Sep 2014 Status changed from not stated to completed.
- 03 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.